Home › Companies › CNTB

Connect Biopharma

CNTB Lead: Phase 2 1 Biotech Distilled article ↓

Respiratory Protein

Most recent annual filing: 2026-03-31

Pipeline (4 active programs)

rademikibart

CBP-201

Protein Target: IL-4Rα

Asthma Phase 2 subcutaneous
Asthma Phase 1 intravenous
Chronic Obstructive Pulmonary Disease Phase 2 subcutaneous
Chronic Obstructive Pulmonary Disease Phase 1 intravenous

Discontinued (1)

rademikibart — Atopic Dermatitis · Connect has decided to not currently pursue further development of rademikibart for AD

Biotech Distilled coverage (1)

2026-06-08 Connect Biopharma (CNTB) - Scientific Deep Dive for Rademikibart and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.